全文获取类型
收费全文 | 11653篇 |
免费 | 957篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 360篇 |
妇产科学 | 341篇 |
基础医学 | 1246篇 |
口腔科学 | 388篇 |
临床医学 | 1090篇 |
内科学 | 2453篇 |
皮肤病学 | 380篇 |
神经病学 | 1008篇 |
特种医学 | 867篇 |
外国民族医学 | 19篇 |
外科学 | 1421篇 |
综合类 | 164篇 |
一般理论 | 4篇 |
预防医学 | 918篇 |
眼科学 | 548篇 |
药学 | 633篇 |
中国医学 | 3篇 |
肿瘤学 | 732篇 |
出版年
2019年 | 130篇 |
2018年 | 191篇 |
2017年 | 116篇 |
2016年 | 129篇 |
2015年 | 133篇 |
2014年 | 203篇 |
2013年 | 305篇 |
2012年 | 399篇 |
2011年 | 424篇 |
2010年 | 233篇 |
2009年 | 237篇 |
2008年 | 371篇 |
2007年 | 456篇 |
2006年 | 416篇 |
2005年 | 469篇 |
2004年 | 407篇 |
2003年 | 394篇 |
2002年 | 385篇 |
2001年 | 376篇 |
2000年 | 420篇 |
1999年 | 332篇 |
1998年 | 171篇 |
1997年 | 156篇 |
1996年 | 161篇 |
1995年 | 145篇 |
1994年 | 118篇 |
1993年 | 130篇 |
1992年 | 283篇 |
1991年 | 294篇 |
1990年 | 297篇 |
1989年 | 326篇 |
1988年 | 307篇 |
1987年 | 343篇 |
1986年 | 312篇 |
1985年 | 276篇 |
1984年 | 226篇 |
1983年 | 211篇 |
1982年 | 129篇 |
1981年 | 109篇 |
1980年 | 115篇 |
1979年 | 194篇 |
1978年 | 144篇 |
1977年 | 114篇 |
1976年 | 130篇 |
1975年 | 113篇 |
1974年 | 139篇 |
1973年 | 150篇 |
1972年 | 128篇 |
1970年 | 104篇 |
1969年 | 103篇 |
排序方式: 共有10000条查询结果,搜索用时 18 毫秒
1.
Guillermo Garcia-Manero Antonio Almeida Pierre Fenaux Norbert Gattermann Aristoteles Giagounidis Stuart L. Goldberg Keiya Ozawa Jerry Weaver Valeria Santini 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(4):213-219.e4
BackgroundIn the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).Patients and MethodsThis analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the effect of lenalidomide dose reductions on response. Clinical benefit was a composite endpoint defined as RBC-TI, transfusion reduction ≥ 4 units packed red blood cells, hemoglobin increase ≥ 1.5 g/dL, or cytogenetic response.ResultsThe rate of clinical benefit was higher with lenalidomide than with placebo (31.9% vs. 3.8%). The ratio of response (RBC-TI and clinical benefit) to risk (hematologic AEs) favored lenalidomide over placebo. Patients who underwent ≥ 1 lenalidomide dose reduction had a longer duration of treatment, received a higher cumulative dose, and were more likely to experience clinical benefit versus patients without dose reductions.ConclusionDespite the occurrence of hematologic AEs, the overall benefit-risk profile supported lenalidomide treatment. Appropriate management of hematologic AEs by dose reductions may help patients with myelodysplastic syndromes to remain on treatment and achieve clinical benefit. 相似文献
2.
Li Bai Saeha Shin Richard T. Burnett Jeffrey C. Kwong Perry Hystad Aaron van Donkelaar Mark S. Goldberg Eric Lavigne Scott Weichenthal Randall V. Martin Ray Copes Alexander Kopp Hong Chen 《International journal of cancer. Journal international du cancer》2020,146(9):2450-2459
Lung and female breast cancers are highly prevalent worldwide. Although the association between exposure to ambient fine particulate matter (PM2.5) and lung cancer has been recognized, there is less evidence for associations with other common air pollutants such as nitrogen dioxide (NO2) and ozone (O3). Even less is known about potential associations between these pollutants and breast cancer. We conducted a population-based cohort study to investigate the associations of chronic exposure to PM2.5, NO2, O3 and redox-weighted average of NO2 and O3 (Ox) with incident lung and breast cancer, using the Ontario Population Health and Environment Cohort (ONPHEC), which includes all long-term residents aged 35–85 years who lived in Ontario, Canada, 2001–2015. Incident lung and breast cancers were ascertained using the Ontario Cancer Registry. Annual estimates of exposures were assigned to the residential postal codes of subjects for each year during follow-up. We used Cox proportional-hazards models adjusting for personal- and neighborhood-level covariates. Our cohorts for lung and breast cancer analyses included ~4.9 million individuals and ~2.5 million women, respectively. During follow-up, 100,146 incident cases of lung cancer and 91,146 incident cases of breast cancer were diagnosed. The fully adjusted analyses showed positive associations of lung cancer incidence with PM2.5 (hazard ratio [HR] = 1.02 [95% CI: 1.01–1.05] per 5.3 μg/m3) and NO2 (HR = 1.05 [95% CI: 1.03–1.07] per 14 ppb). No associations with lung cancer were observed for O3 or Ox. Relationships between PM2.5 and NO2 with lung cancer exhibited a sublinear shape. We did not find compelling evidence linking air pollution to breast cancer. 相似文献
3.
Mohamed E. Salem J. Nicholas Bodor Alberto Puccini Joanne Xiu Richard M. Goldberg Axel Grothey W. Michael Korn Anthony F. Shields William M Worrilow Edward S. Kim Heinz-Josef Lenz John L. Marshall Michael J. Hall 《International journal of cancer. Journal international du cancer》2020,147(10):2948-2956
Microsatellite instability-high (MSI-H) and tumor mutational burden (TMB) are predictive biomarkers for immune-checkpoint inhibitors (ICIs). Still, the relationship between the underlying cause(s) of MSI and TMB in tumors remains poorly defined. We investigated associations of TMB to mismatch repair (MMR) protein expression patterns by immunohistochemistry (IHC) and MMR mutations in a diverse sample of tumors. Hypothesized differences were identified by the protein/gene affected/mutated and the tumor histology/primary site. Overall, 1057 MSI-H tumors were identified from the 32 932 tested. MSI was examined by NGS using 7000+ target microsatellite loci. TMB was calculated using only nonsynonymous missense mutations sequenced with a 592-gene panel; a subset of MSI-H tumors also had MMR IHC performed. Analyses examined TMB by MMR protein heterodimer impacted (loss of MLH1/PMS2 vs. MSH2/MSH6 expression) and gene-specific mutations. The sample was 54.6% female; mean age was 63.5 years. Among IHC tested tumors, loss of co-expression of MLH1/PMS2 was more common (n = 544/705, 77.2%) than loss of MSH2/MSH6 (n = 81/705, 11.5%; P < .0001), and was associated with lower mean TMB (MLH1/PMS2: 25.03 mut/Mb vs MSH2/MSH6 46.83 mut/Mb; P < .0001). TMB also varied by tumor histology: colorectal cancers demonstrating MLH1/PMS2 loss had higher TMBs (33.14 mut/Mb) than endometrial cancers (20.60 mut/Mb) and other tumors (25.59 mut/Mb; P < .0001). MMR gene mutations were detected in 42.0% of tumors; among these, MSH6 mutations were most common (25.7%). MSH6 mutation patterns showed variability by tumor histology and TMB. TMB varies by underlying cause(s) of MSI and tumor histology; this heterogeneity may contribute to differences in response to ICI. 相似文献
4.
5.
6.
We report on four children born with medium to large congenital melanocytic nevi (CMN) with color heterogeneity and irregular surface rugosity. As these patients aged, their nevi evolved to become more homogeneous and lighter in color, and developed a smoother, more even texture. We propose that given this evolution toward benignity, conservative monitoring and management may be appropriate even in the context of atypical‐appearing features at birth. Such knowledge regarding the evolution of these CMN can more accurately guide parents and clinicians in determining whether to biopsy or remove an atypical‐looking lesion early in life for medical or cosmetic reasons. 相似文献
7.
8.
9.
Connie J. Chen Stuart Kaufman Kirk Packo Heidi Stöhr Bernhard H. F. Weber Morton F. Goldberg 《Ophthalmic genetics》2016,37(1):102-108
Background: Mutations in BEST1 account for autosomal dominant vitreoretinochoroidopathy (ADVIRC), a rare inherited retinal dystrophy with presenile cataracts and incomplete anterior segment development. The long-term clinical findings and visual prognosis of these patients continues to evolve over time.Materials and Methods: The retina was assessed by fundus photography, fluorescein angiography, and spectral domain optical coherence tomography. Sanger dideoxy chain-termination sequencing identified mutations in BEST1. Bioinformatic tools were used to predict changes in splicing. An in vitro splicing assay was applied to evaluate for altered pre-mRNA splicing.Results: Long-term follow up of the first ever reported ADVIRC proband revealed progressive foveal atrophy in both eyes 3 decades after his initial presentation. Progressive retinal ischemia, bilateral iris atrophy, and pseudophakodnesis were observed on follow up. The patient was heterozygous for a c.248G?>?A missense mutation in exon 4 of BEST1, affecting a highly conserved transmembrane domain. Although computational prediction models suggest a change in the binding probability of splicing-associated SR proteins, in vitro splicing assays failed to demonstrate an effect of the c.248G?>?A mutation on splicing of BEST1 exon 3 or exon 4.Conclusions: Progressive posterior chorioretinal changes occurred over time in the initial ADVIRC proband, leading to visual loss. The causative mutation in this patient falls in the transmembrane domain of the BEST1 protein, with unclear functional consequences. Although previous studies showed alteration in pre-mRNA splicing, in vitro splicing assays failed to demonstrate this in our patient. 相似文献
10.
Dan B. Rootman Justin Karlin Grant Moore Robert Goldberg 《Orbit (Amsterdam, Netherlands)》2015,34(2):92-98
Purpose: To investigate the relationships between pre-operative marginal reflex distance (MRD), tissue resection length, phenylephrine response, and change in MRD with surgery for a cohort of individuals undergoing Muller’s muscle conjunctival resection (MMCR) surgery.Methods: All cases of MMCR surgery performed over a 13-year period at a single institution were screened for entry. Individuals with adequate photographic documentation and follow up were included. Patients with previous or concurrent upper eyelid, orbital or eyebrow disease of surgery were excluded. Marginal reflex distance (MRD) was calculated based on photographs utilizing public domain software. Data was plotted for inspection and appropriate statistical tests were performed.Results: During the study period 198 eyes fit criteria for analysis. A loose association between tissue resection length and change in MRD with surgery was found (r?=?0.176, p?0.05); this relationship was not significant in ANOVA analysis (p?=?0.367). There was a strong association between MRD change with surgery and pre-operative MRD (r?=?0.498, p?0.01). Approximately 28% of the sample responded to 2.5% phenylephrine drop instillation with a greater than 2?mm increase in MRD. The response to phenylephrine was strongly associated with pre-operative MRD (r?=??0.441, p?0.01). A regression on change in MRD with surgery with tissue resection, phenylephrine response >2?mm and pre-operative MRD as variables revealed a model with pre-operative MRD as the only significant predictor (p?0.01).Conclusion: Tissue resection length and phenylephrine response play small roles relative to pre-operative MRD in the determination of change in MRD with MMCR surgery. 相似文献